Patients with glioblastoma multiforme, a type of brain cancer, who recurred following radiation therapy and Temodal (temozolomide), did not survive longer when treated with the PD-1 inhibitor Opdivo ...

The European Commission has approved Opdivo as a second-line treatment for adults with advanced inoperable, recurrent, or metastatic esophageal squamous cell carcinoma (ESCC), who previously were ...

GE Healthcare and Vanderbilt University Medical Center (VUMC) have established a five-year partnership aimed at developing new diagnostic tools to predict how an immunotherapy will work — as far as ...

PF-06801591 is an immunotherapy that Pfizer is developing for several types of cancer. It is called an anti-PD-1 treatment because it blocks the PD-1 protein on the surface of immune T-cells that can ...

The U.S. Food and Drug Administration (FDA) has suspended two Phase 1 trials assessing Cellectis’ CAR T-cell therapy UCART123 in acute myeloid leukemia (AML) and blastic plasmacytoid dendritic cell ...

The U.S. Food and Drug Administration (FDA) has approved Imfinzi (durvalumab), in combination with standard chemotherapy, as an initial treatment of people with extensive-stage small cell lung cancer ...

The immune system works to protect a person from illness by fighting foreign invaders like viruses and bacteria. It can also recognize harmful changes happening inside the body, like the formation of ...

DNX-2401 is an oncolytic immunotherapy being investigated by DNAtrix for the treatment of cancers, especially brain tumors. Oncolytic viruses, infect and destroy cancer cells while leaving normal ...

Viruses, like the flu virus, try to enter the cells in our body because they need a host to survive.Once inside, the virus begins to use the “machinery” of the cell to make copies of itself, ...

rSIFN-co is a potential cancer therapy that Sichuan Huiyang Life Science and Technology Corporation is developing to treat several types of advanced solid tumors.. How rSIFN-co works. rSIFN-co, or ...

The U.S. Food and Drug Administration (FDA) has granted breakthrough therapy designation to Immunocore‘s tebentafusp (IMCgp100) for HLA-A2 positive, inoperable, or advanced uveal melanoma — a common ...

The U.S. Food and Drug Administration granted breakthrough therapy designation to an investigational combination of Eisai’s Lenvima (lenvatinib) and Merck‘s Keytruda (pembrolizumab) for the treatment ...